CommercialCoverageMedium impact
Thyrogen (Thyrotropin Alfa) (CPB 0515, reviewed 2026-08-05)
Aetna·Oncology, Endocrinology, Nuclear Medicine +1 more·Medical Policy
Effective date
Aug 5, 2026
We identified it
Aug 18, 2026
Summary
Aetna has updated its Clinical Policy Bulletin for Thyrogen (thyrotropin alfa) effective 2026-08-05, clarifying coverage for three specific indications: diagnostic thyroglobulin testing in thyroid cancer follow-up, radioiodine ablation of thyroid remnants, and radioiodine ablation for non-toxic multi-nodular goiter. The policy explicitly excludes coverage for patients with suppressed serum thyroglobulin levels (less than 0.1 ng/ml) and all other off-label indications. Billing teams must ensure claims include appropriate documentation and ICD-10 codes to meet medical necessity criteria.
Action Required
By 2026-08-05: Billing team must update claim submission protocols for Thyrogen (J3240) to require one of three qualifying ICD-10 diagnoses: C73 (malignant neoplasm of thyroid), E04.2 (non-toxic multinodular goiter for ablation only), or Z85.850 (personal history of thyroid cancer). REJECT or hold for clarification any claims for Thyrogen that list serum thyroglobulin levels less than 0.1 ng/ml (suppressed), as these are explicitly non-covered per policy. Providers must document: (1) patient has undergone thyroidectomy or near-total thyroidectomy, (2) which of the three covered indications applies, and (3) that provider is knowledgeable in thyroid cancer management. Update billing system rules to flag claims missing required diagnosis codes or documentation. Flag claims with diagnosis codes outside C73, E04.2, or Z85.850 as requiring prior authorization review, as these may be considered experimental/investigational. Communicate with providers that off-label uses (e.g., for suppressed Tg or other indications) are not covered and will be denied.